CClinicalTrials.gg
CompletedNCT04784312Updated Jun 15, 2022

A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection

A Phase 1 interventional study of 9MW1411 injection and 9MW1411 injection placebo in Staphylococcus Aureus Infection, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 1, first time in human study enrolling approximately 42 healthy adult subjects (18-45 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MW14 in healthy adult volunteers administered as a single IV dose compared with placebo, across 5 cohorts. The 5 dose cohorts will enroll sequentially. Subjects will be followed for safety from the time of Informed Consent through 85 days post dose.

02

Conditions studied

  • Staphylococcus Aureus Infection
03

In context

Staphylococcal Infections

273 studies on the registry are indexed under Staphylococcal Infections; 29 are open to participants now.

This study's enrollment of 42 is below the median of 120 across 177 interventional studies indexed under Staphylococcal Infections.

Browse Staphylococcal Infections studies →

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 53 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Male or female subjects aged 18 to 45 years (including 18 and 45 years).
  2. Weight≥50.0 kg for males, or weight≥45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 26.0 kg/m2 (including cut-off value).
  3. The medical history, physical examination, clinical laboratory tests and other tests related study show no abnormalities, or abnormalities without clinical significance.
  4. Subjects do not have a pregnancy plan, have no sperm and egg donation plans during the screening period and the next 6 months, and take effective contraceptive measures voluntarily.
  5. Are willing to follow study procedures, signed informed consent voluntarily, and ensure that he/she will complete the study according to the program requirements.

Exclusion criteria

Exclusion Criteria:

Prior or current medical conditions:

  1. Health status: clinically significant histories of heart, liver, kidney, digestive tract, nervous system, respiratory system, blood and lymphatic system, immune system, mental, metabolic, and bone abnormalities.
  2. Subjects who have a history of allergies to biological agents or any drug components; those who have a history of allergies and judged by the investigator to be ineligible for enrollment.
  3. Those who undergone acute infection within 2 weeks prior to screening.
  4. Those with abnormalities in pulmonary imaging examination prior to screening and judged to be clinically significant by the investigator.
  5. Those who have undergone surgery within 3 months prior to screening, or who plan to undergo surgery during the study.
  6. Those who cannot tolerate venipuncture or have a history of needle-sickness and blood-sickness.
  7. Those who have a history of drug abuse within 6 months prior to screening.
  8. Use of illicit drugs within 3 months prior to screening.
  9. Those who donated blood within 3 months prior to screening (including component blood), or massive blood loss (≥ 200 mL), or blood transfusions or use of blood products.
  10. Subject (female) who is pregnant or lactating at screening or during the trial.
  11. Subjects have a fertility plan or sperm or egg donation plan at screening and within the next 6 months.
  12. Use of any prescription, over-the-counter, or Chinese herbal medicines within 2 weeks prior to screening.
  13. Those who have been vaccinated within 4 weeks prior to screening or who are scheduled to be vaccinated during the study.
  14. Those who have smoked more than 5 cigarettes per day within 3 months prior to screening.
  15. Those who have consumed more than 14 units of alcohol per week (1 unit of alcohol ≈ 360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 3 months prior to screening, or who cannot abstain from alcohol during the trial.
  16. Those who have special dietary requirements and cannot accept a standard diet.
  17. Those who have participated in drug or medical devices clinical trials within 3 months prior to screening.
  18. Those who have previously used immunosuppressants or monoclonal antibodies for any reason.
  19. Those with abnormal vital signs with clinical significance: diastolic blood pressure≤50 mmHg or ≥90 mmHg, pulse≤50 beats/min or ≥100 beats/min, body temperature (ear temperature) \<35.5°C or >37.5°C, respiration>20 breaths/min. The specific situation will be comprehensively determined by the investigator.
  20. Those with abnormalities in laboratory tests and auxiliary examinations that are judged by the investigator to be clinically significant.
  21. Those who have one or more clinically significant tests of hepatitis B virological markers, hepatitis C virus antibodies, anti-human immunodeficiency virus antibodies, or anti-Treponema pallidum-specific antibodies.
  22. Female subjects with a positive blood pregnancy test at screening.
  23. Alcohol breath test results greater than 0.0 mg/100 ml or positive drug screening (morphine, icenarcotics [methamphetamine], ketamine, ecstasy [methylenedioxyamphetamine], cannabis [tetrahydrocannabinolate], erythroxylin).
  24. Subjects who is inappropriate to participate in the trial due to any reasons as determined by the investigator.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    9MW1411 injection

    Combination Product: 9MW1411 injection

  • Experimental
    9MW1411 injection placebo

    Combination Product: 9MW1411 injection placebo

Interventions

  • Combination product9MW1411 injection

    9MW1411 injection

  • Combination product9MW1411 injection placebo

    9MW1411 injection placebo

06

What researchers measure

Primary outcomes

  1. Adverse Event

    safety evaluation

    Time frame: 12 weeks

  2. Serious Adverse Event

    safety evaluation

    Time frame: 12 weeks

07

Study locations

1 site
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 200040, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04784312
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Collaborators
Huashan Hospital
Responsible party
Sponsor
First posted
Mar 5, 2021
Start date
Apr 16, 2021
Primary completion
Aug 17, 2021
Completion
Aug 17, 2021
Last update
Jun 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion